Related Experiment Video
Updated: Apr 21, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
MicroRNA-30d regulates cardiomyocyte pyroptosis by directly targeting foxo3a in diabetic cardiomyopathy
1Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), Harbin Medical University, Harbin 150081, China.
Abstract:
Diabetic cardiomyopathy is a common cardiac condition in patients with diabetes mellitus, which can result in cardiac hypertrophy and subsequent heart failure, associated with pyroptosis, the pro-inflammatory programmed cell death. MicroRNAs (miRNAs), small endogenous non-coding RNAs, have been shown to be involved in diabetic cardiomyopathy. However, whether miRNAs regulate pyroptosis in diabetic cardiomyopathy remains unknown. Our study revealed that mir-30d expression was substantially increased in streptozotocin (STZ)-induced diabetic rats and in high-glucose-treated cardiomyocytes as well. Upregulation of mir-30d promoted cardiomyocyte pyroptosis in diabetic cardiomyopathy; conversely, knockdown of mir-30d attenuated it. In an effort to understand the signaling mechanisms underlying the pro-pyroptotic property of mir-30d, we found that forced expression of mir-30d upregulated caspase-1 and pro-inflammatory cytokines IL-1β and IL-18. Moreover, mir-30d directly repressed foxo3a expression and its downstream protein, apoptosis repressor with caspase recruitment domain (ARC). Furthermore, silencing ARC by siRNA mimicked the action of mir-30d: upregulating caspase-1 and inducing pyroptosis. These findings promoted us to propose a new signaling pathway leading to cardiomyocyte pyroptosis under hyperglycemic conditions: mir-30d↑→foxo3a↓→ ARC↓→caspase-1↑→IL-1β, IL-18↑→pyroptosis↑. Therefore, mir-30d may be a promising therapeutic target for the management of diabetic cardiomyopathy.
Insights
MicroRNA-30d (mir-30d) promotes pyroptosis, a form of cell death, in diabetic cardiomyopathy. Targeting mir-30d may offer a new treatment strategy for this heart condition.
Area of Science:
- Cardiology
- Molecular Biology
- Biochemistry
Background:
- Diabetic cardiomyopathy, a complication of diabetes mellitus, involves cardiac hypertrophy, heart failure, and pyroptosis (programmed cell death).
- MicroRNAs (miRNAs) are implicated in diabetic cardiomyopathy, but their role in regulating pyroptosis is unclear.
Purpose of the Study:
- To investigate the role of miRNAs in pyroptosis within diabetic cardiomyopathy.
- To elucidate the specific signaling pathway involving mir-30d in this process.
Main Methods:
- Utilized streptozotocin (STZ)-induced diabetic rat models and high-glucose-treated cardiomyocytes.
- Assessed mir-30d expression, pyroptosis markers (caspase-1, IL-1β, IL-18), and key regulatory proteins (foxo3a, ARC).
- Employed techniques such as miRNA mimics, inhibitors, and siRNA for gene silencing.
Main Results:
- Mir-30d expression was significantly upregulated in diabetic conditions.
- Overexpression of mir-30d promoted cardiomyocyte pyroptosis, while its inhibition attenuated it.
- Mir-30d was found to directly repress foxo3a, leading to decreased ARC expression and subsequent activation of caspase-1 and inflammatory cytokines.
Conclusions:
- A novel signaling pathway (mir-30d → foxo3a → ARC → caspase-1 → pyroptosis) was identified in diabetic cardiomyopathy under hyperglycemic conditions.
- Mir-30d represents a potential therapeutic target for managing diabetic cardiomyopathy.
Related Concept Videos
MicroRNAs
MicroRNAs

